Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of ONO-2506PO in Patients With Alzheimer's Disease

This study has been completed.
Information provided by (Responsible Party):
Ono Pharmaceutical Co. Ltd ( Ono Pharma USA Inc ) Identifier:
First received: May 24, 2004
Last updated: June 12, 2012
Last verified: June 2012
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.

Condition Intervention Phase
Alzheimer's Disease
Drug: ONO-2506PO
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effects of ONO-2506PO in Patients With Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Ono Pharmaceutical Co. Ltd:

Primary Outcome Measures:
  • Cognitive Function Scale
  • Global Function Scale

Secondary Outcome Measures:
  • ADL Scale
  • Psychiatric Symptom Scale

Enrollment: 647
Study Start Date: June 2004
Study Completion Date: July 2007

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable Alzheimer's Disease using NINCDS/ADRDA criteria
  • Standardized MMSE Score of 13 to 24 points (inclusive)
  • Modified Hachinski score equal or less than 4

Exclusion Criteria:

  • Serious systemic disease that may preclude survival to study completion
  • Other illnesses that may include dementive features
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00083421

  Show 87 Study Locations
Sponsors and Collaborators
Ono Pharma USA Inc
  More Information

Responsible Party: Ono Pharma USA Inc Identifier: NCT00083421     History of Changes
Other Study ID Numbers: ONO-2506POU010
Study First Received: May 24, 2004
Last Updated: June 12, 2012

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on May 23, 2017